# Micvotabart pelidotin

Source: https://onco.cc/drugs/micvotabart-pelidotin/  
OnCo record `micvotabart-pelidotin` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Micvotabart pelidotin is an experimental antibody-drug conjugate from Pyxis Oncology, in phase 1 trials for advanced solid tumours, with a focus on recurrent or metastatic head and neck squamous cell carcinoma.

## Summary

Micvotabart pelidotin (PYX-201) is an antibody-drug conjugate (auristatin payload) from Pyxis Oncology. Targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tissue around tumour cells and releases an auristatin payload there. Pyxis focuses it on recurrent or metastatic head and neck squamous cell carcinoma; it is in a phase 1 study alone (NCT05720117) and a phase 1/2 study in combination (NCT06795412), both in advanced solid tumours. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: PYX-201; MICVO
- Tags: pipeline; ctgov-ingest
- Code: PYX-201
- Modality: Antibody-drug conjugate (auristatin payload)
- Mechanism: Targets the extradomain-B splice variant of fibronectin (EDB+FN) in the tissue around tumour cells and releases an auristatin payload there.

## Sources

- Pyxis Oncology clinical programmes: https://pyxisoncology.com/clinical-programs/
- ClinicalTrials.gov NCT06795412: https://clinicaltrials.gov/study/NCT06795412
- ClinicalTrials.gov NCT05720117: https://clinicaltrials.gov/study/NCT05720117

## Connected records

- targets: [FN1](https://onco.cc/targets/fn1/)
- companies: [Pyxis Oncology](https://onco.cc/companies/pyxis-oncology/)
- trials: [A Study of PYX-201 in Advanced Solid Tumors](https://onco.cc/trials/nct05720117/), [Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors](https://onco.cc/trials/nct06795412/)

---
JSON: https://onco.cc/api/v1/entities/micvotabart-pelidotin.json